Qube Research & Technologies (QRT)’s Definium Therapeutics DFTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$25.5M	Sell	668,876 -14,025	-2%	-$591K	0.02%	857
2026 Q2	$32.1M	Buy	682,901 +256,846	+60%	+$6.35M	0.03%	682
2026 Q1	$8.05M	Buy	+426,055	New	+$7.23M	0.01%	1406
2024 Q2	–	Sell	-116,327	Closed	-$1.09M	–	4402
2024 Q1	$1.09M	Buy	116,327 +22,678	+24%	+$129K	﹤0.01%	2094
2023 Q4	$343K	Buy	93,649 +84,644	+940%	+$255K	﹤0.01%	2510
2023 Q3	$28.2K	Buy	+9,005	New	+$37K	﹤0.01%	3040

Other funds holding DFTX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Qube Research & Technologies (QRT)'s DFTX Position: Q3 2026 in Review

Qube Research & Technologies (QRT) reduced its Definium Therapeutics (DFTX) stake by 2.1% in Q3 2026, selling an estimated $591K and leaving 668,876 shares worth $25.5M. The position accounts for 0.02% of the portfolio, ranked #857.

Qube Research & Technologies (QRT) first reported a position in DFTX in Q3 2023 and has held it in 6 quarters since. The position peaked at $32.1M in Q2 2026. 253 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

Qube Research & Technologies (QRT) held 668,876 shares of Definium Therapeutics worth $25.5M as of Q3 2026.
Qube Research & Technologies (QRT) sold 14,025 Definium Therapeutics shares in Q3 2026, an estimated $591K.
Definium Therapeutics made up 0.02% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #857 holding.
Qube Research & Technologies (QRT) first reported a position in Definium Therapeutics in Q3 2023 and has held it in 6 quarters since.
Qube Research & Technologies (QRT)'s Definium Therapeutics position peaked at $32.1M in Q2 2026.
253 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.